Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Lofacimig Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Lofacimig: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Lidbree Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Lidbree: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Linafexor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Linafexor: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vinseltinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Vinseltinib: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ProLectin Rx Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
ProLectin Rx: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IOLs (AffaMed Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
IOLs (AffaMed Therapeutics): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
HYNIC-3PRGD2(Foshan Rui Diao) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
HYNIC-3PRGD2(Foshan Rui Diao): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
(S)-Oxiracetam Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
(S)-Oxiracetam: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
RH-Insulin (Sunshine Lake) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
RH-Insulin (Sunshine Lake): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Artificial Saliva (Shenzhen Nanyue) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Artificial Saliva (Shenzhen Nanyue): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tetanus Vaccine,Adsorbed (Cansino) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Tetanus Vaccine,Adsorbed (Cansino): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Human Tetanus Immunoglobulin (SK Plasma) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Human Tetanus Immunoglobulin (SK Plasma): NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.